Hormone Therapy

//Hormone Therapy

Cognition and Hormone Therapy (ADT)

There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well as my own personal experience, I must fall in line and agree with an online published study that shows that men on ADT are likely to experience cognitive impairment of some type. The study was small, as all of the other studies have been, followed [...]

Enzalutamide Prescribing Info Includes New Information

Enzalutamide (Xtandi) has a new, expanded FDA label. The new label conforms with the clinical trial (TERRAIN) results that Xtandi is a superior drug to Casodex (bicalutamide) for men with metastatic castration-resistant prostate cancer (CRPC). The updated product label shows enzalutamide reduces the risk of radiographic progression or death by 40% vs. bicalutamide. Median radiographic progression-free survival was 19.5 months with enzalutamide compared with 13.4 months with bicalutamide. Steven Benner, MD, senior vice president, therapeutic area head for oncology development, Astellas, said in a statement, "The addition of data from the TERRAIN trial continues to build the body of evidence [...]

By | October 26th, 2016|Casodex, enzalutamide, Uncategorized, Xtandi|0 Comments

Degarelix or Leuprolide – Today’s Question Explored

There are many different types of drugs used for hormone therapy in the treatment of prostate cancer. One of the newer classes of drugs include the GnRH antagonists. Degarelix (aka Firmagon) is the one drug in this class that is currently approved for prostate cancer. Degarelix, like the other hormone therapy drugs, was developed to suppress testosterone. What makes this class of drugs different is that it also avoids the flare phenomenon that is observed with the GnRH agonists like Lupron. The flare phenomenon, where the body initially pumps out additional levels of testosterone in response to the GnRH agonist [...]

Efficacy of Enzalutamide in Castrate-Resistant Prostate Cancer in Men with Visceral Metastases

We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with non-visceral metastases. The important question we need to understand is what, of our currently available treatments, might be effective for this more aggressive and deadly type of prostate cancer? Results of the phase 3 AFFIRM clinical trial have demonstrated that treatment with the androgen receptor inhibitor enzalutamide (Xtandi) resulted in significant improvements in outcomes for men with mCRPC. This blog post discusses the efficacy of enzalutamide among men from the AFFIRM trial who had visceral disease. Men who were in [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー